Zurück zum Zitat Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu C‑H, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih J‑Y, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M, Chu Q, Cortot A, Pujol J‑L, Moro-Sibilot D, Fabre E, Lamour C, Bischoff H, Kollmeier J, Reck M, Kimmich M, Engel-Riedel W, Hammerschmidt S, Schütte W, Syrigos K, Ho JCM, Au K‑H, Novello S, Ardizzoni A, Pasello G, Gregorc V, Del Conte A, Galetta D, Takahashi T, Nakagawa K, Nishio M, Yoh K, Seto T, Imamura F, Kumagai T, Hotta K, Goto Y, Hosomi Y, Sakai H, Takiguchi Y, Kim YH, Kurata T, Yamaguchi H, Daga H, Okamoto I, Satouchi M, Ikeda S, Kasahara K, Atagi S, Azuma K, Kumagai T, Aoe K, Kumagai T, Aoe K, Horio Y, Yamamoto N, Tanaka H, Watanabe S, Nogami N, Ozaki T, Koyama R, Hirashima T, Kaneda H, Tomii K, Fujita Y, Seike M, Nishimura N, Kato T, Ichiki M, Saka H, Hirano K, Nakahara Y, Sugawara S, Park K, Kim S‑W, Min YJ, Lee HW, Kang J‑H, An HJ, Lee KH, Kim J‑S, Lee G‑W, Lee SY, Alexandru A, Udrea AA, Juan-Vidal Ó, Nadal-Alforja E, Gil-Bazo I, Ponce-Aix S, Paz-Ares L, Rubio-Viqueira B, Alonso Garcia M, Felip Font E, Fuentes Pradera J, Coves Sarto J, Lin M‑C, Su W‑C, Hsia T‑C, Chang G‑C, Wei Y‑F, Chiu C‑H, Shih J‑Y, Su J, Cicin I, Goksel T, Harputluoglu H, Ozyilkan O, Henning I, Popat S, Hatcher O, Mileham K, Acoba J, Garon E, Jung G, Raj M, Martin W, Dakhil S (2019) Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:1655–1669. https://doi.org/10.1016/S1470-2045(19)30634-5CrossRefPubMed
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu C‑H, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih J‑Y, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M, Chu Q, Cortot A, Pujol J‑L, Moro-Sibilot D, Fabre E, Lamour C, Bischoff H, Kollmeier J, Reck M, Kimmich M, Engel-Riedel W, Hammerschmidt S, Schütte W, Syrigos K, Ho JCM, Au K‑H, Novello S, Ardizzoni A, Pasello G, Gregorc V, Del Conte A, Galetta D, Takahashi T, Nakagawa K, Nishio M, Yoh K, Seto T, Imamura F, Kumagai T, Hotta K, Goto Y, Hosomi Y, Sakai H, Takiguchi Y, Kim YH, Kurata T, Yamaguchi H, Daga H, Okamoto I, Satouchi M, Ikeda S, Kasahara K, Atagi S, Azuma K, Kumagai T, Aoe K, Kumagai T, Aoe K, Horio Y, Yamamoto N, Tanaka H, Watanabe S, Nogami N, Ozaki T, Koyama R, Hirashima T, Kaneda H, Tomii K, Fujita Y, Seike M, Nishimura N, Kato T, Ichiki M, Saka H, Hirano K, Nakahara Y, Sugawara S, Park K, Kim S‑W, Min YJ, Lee HW, Kang J‑H, An HJ, Lee KH, Kim J‑S, Lee G‑W, Lee SY, Alexandru A, Udrea AA, Juan-Vidal Ó, Nadal-Alforja E, Gil-Bazo I, Ponce-Aix S, Paz-Ares L, Rubio-Viqueira B, Alonso Garcia M, Felip Font E, Fuentes Pradera J, Coves Sarto J, Lin M‑C, Su W‑C, Hsia T‑C, Chang G‑C, Wei Y‑F, Chiu C‑H, Shih J‑Y, Su J, Cicin I, Goksel T, Harputluoglu H, Ozyilkan O, Henning I, Popat S, Hatcher O, Mileham K, Acoba J, Garon E, Jung G, Raj M, Martin W, Dakhil S (2019) Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:1655–1669.
https://doi.org/10.1016/S1470-2045(19)30634-5CrossRefPubMed